DK0679187T4 - Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV - Google Patents

Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV

Info

Publication number
DK0679187T4
DK0679187T4 DK94904568T DK94904568T DK0679187T4 DK 0679187 T4 DK0679187 T4 DK 0679187T4 DK 94904568 T DK94904568 T DK 94904568T DK 94904568 T DK94904568 T DK 94904568T DK 0679187 T4 DK0679187 T4 DK 0679187T4
Authority
DK
Denmark
Prior art keywords
protein
pct
native
ectodomains
glycosylated
Prior art date
Application number
DK94904568T
Other languages
Danish (da)
English (en)
Other versions
DK0679187T3 (da
Inventor
Manfred Schawaller
Original Assignee
Manfred Schawaller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6478309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0679187(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Manfred Schawaller filed Critical Manfred Schawaller
Publication of DK0679187T3 publication Critical patent/DK0679187T3/da
Application granted granted Critical
Publication of DK0679187T4 publication Critical patent/DK0679187T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK94904568T 1993-01-16 1994-01-12 Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV DK0679187T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4301017 1993-01-16
PCT/DE1994/000022 WO1994016081A1 (de) 1993-01-16 1994-01-12 Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv

Publications (2)

Publication Number Publication Date
DK0679187T3 DK0679187T3 (da) 1997-12-08
DK0679187T4 true DK0679187T4 (da) 2001-09-17

Family

ID=6478309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94904568T DK0679187T4 (da) 1993-01-16 1994-01-12 Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV

Country Status (9)

Country Link
US (1) US6140059A (el)
EP (1) EP0679187B2 (el)
JP (1) JP3658690B2 (el)
AT (1) ATE153380T1 (el)
DE (2) DE59402827D1 (el)
DK (1) DK0679187T4 (el)
ES (1) ES2102815T5 (el)
GR (1) GR3023717T3 (el)
WO (1) WO1994016081A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2002533124A (ja) 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
JP2003523721A (ja) * 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
DE69938062T2 (de) 1998-12-31 2009-01-15 Novartis Vaccines and Diagnostics, Inc., Emeryville Modifizierte hiv env polypeptide
US20030194800A1 (en) * 2001-08-31 2003-10-16 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2384271A1 (en) * 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
US7179468B1 (en) 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
JP4302513B2 (ja) * 2001-07-05 2009-07-29 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2007502623A (ja) * 2003-05-09 2007-02-15 リサーチ ディベロップメント ファウンデーション 膜タンパク質におけるフリンプロテアーゼ開裂部位の挿入およびその使用法
US7358334B1 (en) 2003-11-14 2008-04-15 Jay W Chaplin B cell-targeted toxins for humoral immune response reduction and methods of use thereof
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
AU2010222929B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
CA2754743C (en) 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AR085573A1 (es) 2011-03-25 2013-10-09 Baylor Res Inst Composiciones y metodos de inmunizacion contra el virus de la hepatitis c
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3731874A1 (de) * 1987-09-18 1989-03-30 Schering Ag Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
EP0519001B2 (en) † 1990-03-09 2007-12-19 Novartis Vaccines and Diagnostics, Inc. PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.

Also Published As

Publication number Publication date
DK0679187T3 (da) 1997-12-08
JPH08505769A (ja) 1996-06-25
EP0679187B1 (de) 1997-05-21
ATE153380T1 (de) 1997-06-15
EP0679187B2 (de) 2001-07-04
DE4400659C2 (de) 1995-07-27
ES2102815T3 (es) 1997-08-01
JP3658690B2 (ja) 2005-06-08
EP0679187A1 (de) 1995-11-02
US6140059A (en) 2000-10-31
DE59402827D1 (de) 1997-06-26
ES2102815T5 (es) 2001-11-16
WO1994016081A1 (de) 1994-07-21
DE4400659A1 (de) 1994-07-21
GR3023717T3 (en) 1997-09-30

Similar Documents

Publication Publication Date Title
DK0679187T4 (da) Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV
DK217288D0 (da) Dna, der indkoder t-celleoverfladeproteinet t4, og anvendelse af t4-fragmenter ved behandling af aids
DK33190D0 (da) Hiv-3 retrovirus og anvendelse heraf
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
ES2009350A6 (es) Procedimiento para la preparacion de vectores de expresion que codifican una nueva proteina.
WO2003038057A3 (en) Genetic vaccine against human immunodeficiency virus
RU98101904A (ru) Рекомбинантный вирус mva и его использование
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
ATE397014T1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
Weiss et al. Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
WO2002068654A3 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
Giron et al. Human foamy virus polypeptides: identification of env and bel gene products
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
IL158981A0 (en) Tsg101 as inhibitor of hiv production
Barnes Strategies for an AIDS Vaccine: In their attempts to develop a vaccine against AIDS, many scientists focus on raising antibodies to a protein from the AIDS virus, a strategy that some researchers think may require modification
ATE438714T1 (de) Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
BE1000167A4 (fr) Antigene du virus de l'hepatite b et procede pour sa production.
ATE284709T1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
ATE369427T1 (de) Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine
Li et al. Role of pH in syncytium induction and genome uncoating of avian infectious bronchitis coronavirus (IBV)
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek